Hemostemix Inc. (CVE:HEM – Get Free Report) reached a new 52-week high during mid-day trading on Friday . The stock traded as high as C$0.10 and last traded at C$0.11, with a volume of 15850 shares traded. The stock had previously closed at C$0.10.
Hemostemix Stock Up 5.0 %
The business’s 50 day simple moving average is C$0.08 and its 200 day simple moving average is C$0.06. The stock has a market cap of C$9.15 million, a price-to-earnings ratio of -5.25 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- The Risks of Owning Bonds
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Are Penny Stocks a Good Fit for Your Portfolio?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Roth IRA Calculator: Calculate Your Potential Returns
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
